This article first appeared on GuruFocus .
Release Date: November 10, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Global Health Ltd ( BOM:543654 ) commenced operations at its sixth facility, Medanta Noida, which is a 550-bed state-of-the-art hospital.
-
The company announced plans to establish a 400+ bed super specialty hospital in Guwahati, expanding its reach in the northeast region.
-
Consolidated total income for Q2 FY 2026 was INR11,189 million, a 15% increase compared to the same quarter last year.
-
Profit after tax for the period was INR1,584 million, showing a strong year-on-year growth of 21%.
-
International patients' revenue increased by 49% year-on-year, driven by increased international patient volume.
Negative Points
-
Medanta Noida reported an EBITDA loss of INR197 million in its first month of operations, reflecting initial ramp-up challenges.
-
EBITDA growth for mature hospitals was only 2.2% year-on-year, impacted by additional manpower costs and lower incidence of vector-borne diseases.
-
The company faces challenges with CGHS and ECHS payment collections, with realization periods extending up to 9 months.
-
Operational costs for the new Ranchi hospital are not separately tracked, making it difficult to assess its financial performance.
-
Insurance empanelments for the Noida hospital are still pending, potentially affecting revenue from insured patients.
Q & A Highlights
-
Warning! GuruFocus has detected 1 Warning Sign with BOM:543654.
-
Is BOM:543654 fairly valued? Test your thesis with our free DCF calculator.
Q: Are the increased manpower costs in mature hospitals expected to stabilize, and when can we expect EBITDA growth to align with revenue growth? A: The CFO explained that the increased manpower costs are partly due to the expansion of facilities and the addition of specialties. They expect growth in Ranchi as the new unit grows and additional specialties are added. The CFO anticipates that EBITDA growth will align more closely with revenue growth in the coming quarters, especially when viewed on a 12-month basis rather than quarterly.
Q: With the Noida unit's strong start, can it achieve cost break-even within 12 months of operations? A: The CFO stated that while Medanta has a track record of achieving operational breakeven quickly, they focus on long-term investments in resources and infrastructure. They are optimistic about Noida's potential but prefer not to speculate on the exact timeline for breakeven.
Q: How is the competitive landscape in the NCR market affecting talent acquisition and retention, especially with the new Noida unit? A: The CFO noted that there has been no significant attrition in the Gurugram unit and emphasized that attracting and retaining high-quality clinical talent remains a challenge across major markets. However, Medanta is considered an attractive place for doctors, as evidenced by the successful hiring for the Noida unit.
Q: What is the status of insurance empanelments for the Noida Hospital, and when are they expected to be completed? A: The CFO mentioned that they are working closely with insurance providers to expedite the empanelment process. They hope to have most empanelments completed by the end of the year, if not sooner.
Q: Can you provide an update on the additional 110 beds commissioned in Ranchi and the progress of ongoing projects in South Delhi and Pitampura? A: The CFO reported that Ranchi's volumes have grown by about 15% year-on-year, and they are working on empanelments for the new facility. For South Delhi and Pitampura, construction activities have commenced or are awaiting approval. All projects are expected to take about 3 to 4 years to complete.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
